Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 228 participants.

Also called NCT04980027

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 228 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04980027
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
India (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04980027. Allocation not applicable; no masking; primary purpose treatment. Start 2021-06-07 (actual); primary completion 2022-12-23 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs
Acronym
SAFEGUARD
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Insulin glargine (U300)
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct04980027
Content hash
8f78cffd62d446506ce4a910b15d67ad4596ccda156ab30db586ac4158cd153d